icon-folder.gif   Conference Reports for NATAP  
 
  64rd Annual Meeting of the
American Association for the
Study of Liver Diseases
Washington, DC Nov 1-5 2013
Back grey_arrow_rt.gif
 
 
 
Efficacy and Safety of Sofosbuvir in Patients According to Fibrosis Stage: An Analysis of Phase 3 Data
 
 
  Reported by Jules Levin
AASLD Nov 1-4 2013 Wash DC
 
Keyur Patel,1 Stuart C. Gordon,2 Aasim M. Sheikh,3 Ziad Younes,4 Di An,5 Shu-Min Chuang,5 Julie Ma,5 John McNally,5 Luisa M. Stamm,5
Diana M. Brainard,5 William T. Symonds,5 John G. McHutchison,5 Ronald Nahass,6 Eric M. Yoshida,7 Henk Reesink,8 David R. Nelson9
 
1Duke University Medical Center, Durham, NC; 2Henry Ford Health System, Detroit, MI; 3Gastrointestinal Specialists of Georgia, Marietta, GA; 4Gastro One, Germantown, TN; 5Gilead Sciences, Inc., Foster City, CA; 6ID Care, Hillsborough, NJ; 7University of British Columbia, Vancouver, British Columbia, Canada; 8Academic Medical Center, Amsterdam, the Netherlands; 9University of Florida, Gainesville, FL
 
AASLD: Gilead at AASLD: Sofosbuvir for GT 3, 2 and 1 - (11/18/13)
 

AASLD1.gif

AASLD2.gif

AASLD3.gif

AASLD4.gif

AASLD5.gif

AASLD: Sofosbuvir + Ribavirin for 12 or 24 Weeks for Patients With HCV Genotype 2 or 3: the VALENCE Trial - (11/04/13)

AASLD6.gif

AASLD7.gif

AASLD8.gif

AASLD9.gif

AASLD10.gif